Immutep (ASX:IMM) Accumulated Depreciation: A$0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Immutep Accumulated Depreciation?

Immutep ASX:IMM +1.96% Accumulated Depreciation is A$0.00 Mil as of Mar. 2026. The stock has 1 warning sign investors should review.

Note: A negative number here means the assets are depreciated. When depricates more, the absolute value gets bigger.

Immutep's quarterly accumulated depreciation increased from Sep. 2025 (A$0.00 Mil) to Dec. 2025 (A$-0.77 Mil) but then stayed the same from Dec. 2025 (A$-0.77 Mil) to Mar. 2026 (A$0.00 Mil).

Immutep's annual accumulated depreciation increased from Jun. 2023 (A$-0.65 Mil) to Jun. 2024 (A$-0.69 Mil) and increased from Jun. 2024 (A$-0.69 Mil) to Jun. 2025 (A$-0.74 Mil).

Immutep Accumulated Depreciation Related Terms

Immutep Accumulated Depreciation Historical Data

* Premium members only.

The historical data trend for Immutep's Accumulated Depreciation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Immutep Accumulated Depreciation Chart

Immutep Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25 Jun26
Accumulated Depreciation
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.63 -0.65 -0.69 -0.74 0.00

Immutep Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Accumulated Depreciation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.74 0.00 -0.77 0.00 0.00

Immutep Accumulated Depreciation Calculation

The cumulative depreciation of an asset up to a single point in its life. Regardless of the method used to calculate it, the depreciation of an asset during a single period is added to the previous period's accumulated depreciation to get the current accumulated depreciation.

What does a Accumulated Depreciation of A$0.00 Mil mean?
Immutep (ASX:IMM) has a Accumulated Depreciation of A$0.00 Mil as of Mar. 2026. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on Immutep and its competitors.
Is Immutep's Accumulated Depreciation too high?
Immutep's current Accumulated Depreciation is A$0.00 Mil.
How does Immutep's Accumulated Depreciation compare to VRTX and REGN?
Immutep's Accumulated Depreciation of A$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accumulated Depreciation for a Biotechnology company?
A good Accumulated Depreciation depends on the Biotechnology industry context. However, Accumulated Depreciation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accumulated Depreciation mean?
A high Accumulated Depreciation can signal that a stock is expensive relative to its fundamentals. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on Immutep and its competitors. Immutep's current Accumulated Depreciation is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immutep stock overvalued right now?
Immutep (ASX:IMM) has a current Accumulated Depreciation of A$0.00 Mil. The current Accumulated Depreciation is A$0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accumulated Depreciation calculated?
Accumulated Depreciation is calculated from a company's financial statements. For Immutep (ASX:IMM), the current Accumulated Depreciation is A$0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Immutep Business Description

Address 264 George Street, Level 32, Australia Square, Sydney, NSW, AUS, 2000
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.